The proposed renewal of the Johns Hopkins University (JHU) Center will continue to be led by Director Dr. Jusfin C McArthur. To manage the Center, centralize administrative functions, and most efficiently support the Center-affiliated faculty at JHU, we propose to have the same leadership for the Administrative Core (AC) as for the overall Center's Executive Committee. The AC will be supported by the Center's Administrative Assistant. The AC will serve as the administrative base of the Center and will continue to be housed within the University's Department of Neurology, located on the Johns Hopkins Medical Institutions (JHMI) campus which will enable efficient management across the three affiliated Schools of Medicine (SOM), Bloomberg School of Public Health (BSPH), and School of Nursing (SON). The rafionale for a centralized AC is to have stream lined management and administration in order to maximize efficiency of personnel, resources and ease of use for CFAR researchers, provide overall scientific and programmafic leadership, fiscal oversight and support, and to integrate communicafions and informafion resources to maximize CFAR utility, value, and cohesiveness in support of HIV research at Johns Hopkins. Administrative and financial management, as well as compliance oversight, will be managed through the Office of the Vice Dean for Research in the School of Medicine. The overarching theme of the Center is the development of novel therapeutics targeting sustained CNS inflammation for HIV-associated neurocognitive disorders (HAND). We have identified this as a high priority on the basis of our institutional strengths, our studies of neuropathogenesis both in humans and SIV encephalitis models, and the confinuing importance in clinical care of these disorders.
HIV/AIDS is a major threat to global health and urban America, and HIV-associated-neurocognitive dysfunction remains prevalent even in HAART-treated people. Our research suggests that one ofthe drivers for this is sustained inflammation within the brain. Our Center has helped to coordinate and catalyze scientific and clinical resources at JHU to generate novel approaches to therapy.
|Sacktor, Ned; Nakasujja, Noeline; Redd, Andrew D et al. (2014) HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metab Brain Dis 29:261-8|
|Meulendyke, Kelly A; Croteau, Joshua D; Zink, M Christine (2014) HIV life cycle, innate immunity and autophagy in the central nervous system. Curr Opin HIV AIDS 9:565-71|
|Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6|
|Gamaldo, Charlene E; Gamaldo, Alyssa; McArthur, Justin C et al. (2014) Reply: To PMID 23722610. J Acquir Immune Defic Syndr 65:e124-5|
|Hulgan, Todd; Levinson, Rebecca T; Gerschenson, Mariana et al. (2014) Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. AIDS 28:1625-33|
|Yu, Ian W; Espinoza, Diego A; McAlexander, Melissa A et al. (2014) OpenArray profiling reveals no differential modulation of miRNA by positive and negative CD4+ T cell immunoselection. Exp Hematol 42:11-3|
|Figuera-Losada, Mariana; Rojas, Camilo; Slusher, Barbara S (2014) Inhibition of microglia activation as a phenotypic assay in early drug discovery. J Biomol Screen 19:17-31|
|Bora, Adriana; Ubaida Mohien, Ceereena; Chaerkady, Raghothama et al. (2014) Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. J Neurovirol 20:457-65|
|Bae, Mihyun; Patel, Neha; Xu, Haoxing et al. (2014) Activation of TRPML1 clears intraneuronal A? in preclinical models of HIV infection. J Neurosci 34:11485-503|
|Meulendyke, Kelly A; Queen, Suzanne E; Engle, Elizabeth L et al. (2014) Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 20:591-602|
Showing the most recent 10 out of 60 publications